Alnylam Pharmaceuticals Inc. is offering outcomes-based contracts for its small interfering RNA (siRNA) therapeutic Onpattro in the rare disease of hereditary transthyretin-mediated amyloidosis. The drug, which has an annual list price of $450,000, was shipped to customers within 48 hours of US FDA approval on Aug. 10.
FDA approval was a breakthrough in a number of respects, as Onpattro (patisiran) is the first RNAi therapeutic approved in the US and the first drug cleared for